Thubrikar Aortic Valve partners with MAC’s MEDICAL Group

As part of an exclusive European distribution agreement, Mr. Cicin-Sain, MAC’s MEDICAL Group, and its affiliates will help finance up to 50 implants needed for CE Mark approval of the Optimum TAVI System™. They will also have the option to invest an additional $2 million in Thubrikar Aortic Valve.

Mr. Cicin-Sain has already funded three recent implants in Poland through his investment in the company, alongside heart specialists, Labcor Laboratorios of Brazil, affiliates of the China Cardiovascular Research Foundation, and other angel investors.

These implants show consistent ease of valve delivery and strong performance of the Optimum TAVI system. MAC’s MEDICAL Group also plans to expand the CE Mark trial into Croatia, Serbia, and additional countries.

Read More:Kotoba Technologies Raises $10M in Additional Seed Funding

To date, the Optimum TAV has been successfully implanted in 16 patients, and the first patient treated is doing well after 7 years. This data will soon be submitted for publication in the Journal of the American College of Cardiology: Cardiovascular Interventions (JACC).

The Optimum TAVI system has also been named “Top Aortic Valve Implantation System 2026” by MED TECH Outlook. A detailed interview with Dr. Thubrikar, author of the 1991 textbook The Aortic Valve, is available in the June 1 issue and on the publication’s website.

Dr. Mano Thubrikar, the Company’s Founder and President, stated, “We are very excited to partner with MAC’s MEDICAL Group for expanding and supporting the completion of our CE Mark Trial, and for their vast experience with European marketing and sales of implantable cardiovascular devices.”

Dr. Trebacz remarked, “The hemodynamic performance of the Optimum Valve has been outstanding in all patients throughout up to four years of follow-up. In particular, the results are exceptionally encouraging when compared with my extensive experience over many years using commercially available devices in patients with similarly small annuli. The consistently excellent outcomes observed with the Optimum Valve underscore its remarkable effectiveness in this challenging patient population.”

About Thubrikar Aortic Valve

Founded by Mano Thubrikar, Samir Wadke, and Nikhil Heble, Thubrikar Aortic Valve, Inc. is a privately held medical device company focused on improving the treatment of aortic stenosis. The company aims to provide physicians and patients with a durable transcatheter aortic valve suitable for all patients. Dr. Mano Thubrikar, a leading expert on the aortic valve, founded the company.

About MAC’s MEDICAL Group

MAC’s MEDICAL Group is a leading distributor of cardiovascular implants, interventional radiology, and general surgery products, offering innovative medical and surgical solutions. Headquartered in Austria, the company is made up of 11 local companies operating across 16 European countries, with a team of 34 employees. It focuses on providing high-quality solutions for physicians.

Read More:Tombot Closes $7M Series A3 Growth Financing Round